Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective. Review uri icon

Overview

abstract

  • Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T lymphocytes to target chosen antigens. The targeting of CD19, a cell surface molecule expressed in the vast majority of leukemias and lymphomas, has been successfully translated in the clinic, earning CAR therapy a special distinction in the selection of "cancer immunotherapy" by Science as the breakthrough of the year in 2013. CD19 CAR therapy is predicated on advances in genetic engineering, T cell biology, tumor immunology, synthetic biology, target identification, cell manufacturing sciences, and regulatory compliance-the central tenets of CAR therapy. Here, we review two of these foundations: the genetic engineering approaches and cell types to engineer.

publication date

  • April 26, 2017

Research

keywords

  • Antigens, CD19
  • Cell- and Tissue-Based Therapy
  • Leukemia
  • Lymphoma
  • Mutant Chimeric Proteins
  • Receptors, Antigen, T-Cell
  • T-Lymphocytes

Identity

PubMed Central ID

  • PMC5417838

Scopus Document Identifier

  • 85018686063

Digital Object Identifier (DOI)

  • 10.1016/j.ymthe.2017.03.034

PubMed ID

  • 28456379

Additional Document Info

volume

  • 25

issue

  • 5